CiLostAzol for pReventIon of Recurrent sTroke in Africa

Inclusion Criteria

• •1. Above the age of 30 years; male or female (sex is a biological variable of interest)
• •2. Ischemic stroke or high-risk TIA (ABCD2 score \>= 6) diagnosis no greater than six months before enrollment. Ischemic strokes including lacunar, large vessel atherosclerotic, embolic stroke of undetermined source subtypes are eligible (Ischemic stroke or TIA should be confirmed by either with a cranial CT or MRI within 10 days of symptom onset)
• •3. Aspirin or clopidogrel monotherapy
• •4. Subjects with stroke may present with two or more of the following additional conditions: age ≥65 years, documented diabetes mellitus or previous treatment with oral hypoglycemic or insulin; documented hypertension \>140/90mmHg or previous treatment with anti-hypertensive medications; Mild to moderate renal dysfunction (eGFR 60-30ml/min/1.73m2); Prior myocardial infarction
• •5. Legally competent to sign informed consent or have a LARs who is able to provide consent for them
• •6. In the opinion of the treating physician, patient is medically stable, capable of participating in a randomized trial, and willing and able to attend follow-up.
• •7. Able to do labs at all study intervals (7 visits total)